PDCD1 and melanoma: PET-Stop (EA6192; NCT04462406) is an ECOG/ACRIN cooperative group-led study that will address this in its biomarker-driven trial on early discontinuation of anti-PD-1 therapy in stage IIIB and stage IV melanoma.